Most people meet this diagnosis sideways. An ultrasound for something else mentions a bright or fatty liver. A routine blood test comes back with a mildly raised liver enzyme. Nobody looks worried, you are told to lose a bit of weight, and that is the end of the conversation.
Fatty liver is now estimated to affect around a third of adults worldwide, and it has become the fastest growing reason for liver transplantation in several countries. It is also one of the few serious conditions where the early stage is genuinely reversible. That combination is why it deserves more than a passing mention at the end of an appointment.
What used to be called non-alcoholic fatty liver disease, or NAFLD, is now MASLD: metabolic dysfunction-associated steatotic liver disease. The more advanced inflammatory form, previously NASH, is now MASH. Health services are mid-transition, so you will still see the old names in use, including on the NHS page for the condition.
The rename was not cosmetic. The old name defined the condition by what it was not, which told you nothing. The new one names the actual driver: metabolic dysfunction. You qualify if there is fat in the liver plus at least one metabolic feature, such as a raised waist measurement, raised blood sugar or type 2 diabetes, raised blood pressure, high triglycerides or low HDL cholesterol.
That matters practically, because it means fatty liver is not a liver problem that happens to occur in people with metabolic issues. It is the liver manifestation of the metabolic issue itself.
Early fatty liver is silent, a point the NIDDK overview makes plainly. When symptoms do appear they are vague and easy to attribute elsewhere:
Symptoms that mean the disease has advanced are different and need urgent assessment: yellowing of the eyes or skin, swelling of the abdomen or ankles, easy bruising, confusion, or vomiting blood.
Because the early stage is silent, the diagnosis usually arrives through a scan done for another reason, or through a mildly raised ALT on a blood panel. If you have ever had either and nothing happened next, that is worth revisiting.
Start a symptom search if you have been told you have a fatty liver and were not told what to do about it. It is free, private and takes about a minute.
This is the single most important idea in the condition, and it is the thing most people are never told.
Fat in the liver by itself carries a low risk of serious liver outcomes. What predicts whether someone will develop cirrhosis or liver cancer is fibrosis, the scarring that follows sustained inflammation. Two people can have identical looking fatty livers on ultrasound with completely different futures, and the scan cannot tell them apart.
So the right question after a fatty liver finding is not how much fat, it is how much scarring.
FIB-4 is the free first answer. It is a score calculated from your age, AST, ALT and platelet count, all of which are probably already on your last blood test, and you can run the calculation yourself. A low score makes advanced fibrosis very unlikely and means ordinary monitoring. An indeterminate or high score is the trigger for the next test rather than for alarm.
Elastography is the usual next step. A scan, often branded FibroScan, that measures liver stiffness painlessly in minutes. Some centres use an enhanced liver fibrosis blood test instead.
Biopsy is now rarely needed and is reserved for uncertain cases. The staged approach is set out in the AASLD practice guidance, which is what most hepatology clinics work from.
If you are South Asian, note that this can occur at a lower body mass index than the usual thresholds suggest. Lean MASLD is real, is common in India and across South and East Asia, and is routinely missed because the person does not look like the stereotype. Waist measurement is more informative than weight here.
Weight loss is still the most powerful intervention available, and the targets are specific rather than vague. Around 5 per cent of body weight reduces liver fat. Around 7 to 10 per cent can resolve inflammation and, in a meaningful proportion of people, improve fibrosis. That is a target to agree with a clinician, not a lifestyle aspiration.
Two drugs are now approved for the inflammatory stage. Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, was the first treatment the FDA approved for liver scarring due to fatty liver disease, cleared in March 2024 and given conditional EU authorisation in August 2025. Semaglutide 2.4 mg followed with FDA accelerated approval in August 2025 and conditional EU authorisation in March 2026. Both are authorised for adults with non-cirrhotic MASH and moderate to advanced fibrosis, stage F2 to F3, which is precisely why establishing your fibrosis stage is the gateway to treatment. In its trial, resmetirom resolved MASH without worsening fibrosis in roughly 26 to 30 per cent of patients at one year, against about 10 per cent on placebo.
The ordinary measures still carry most of the weight. Cutting sugar-sweetened drinks and refined carbohydrate, a Mediterranean style of eating, resistance training as well as cardio, treating diabetes and lipids properly, and honesty about alcohol, which compounds the damage even when it is not the primary cause. Coffee has a consistent and reasonably robust association with less fibrosis, which is a rare piece of good news.
What does not work: liver detox supplements, milk thistle as a treatment, and juice cleanses. Some supplements are themselves a cause of liver injury, so tell your doctor everything you take.
The most likely cause of death in someone with fatty liver is cardiovascular, not hepatic. The same metabolic dysfunction damaging the liver is damaging arteries at the same time. Encouragingly, both approved drugs have been associated with reductions in major cardiovascular events as well as liver outcomes.
So a fatty liver result is best read as a flag on the whole metabolic picture. It is the moment to check blood pressure, cholesterol and blood sugar, not just to recheck the liver in a year.
Fatty liver is common, usually silent, and found by accident. The number that matters is fibrosis, not fat, and FIB-4 can be calculated from blood tests you probably already have. Weight loss of 7 to 10 per cent remains the most effective treatment, two drugs are now approved for the inflammatory stage with significant fibrosis, and the biggest risk to your life from this diagnosis runs through your heart.
Start a symptom search, or upload your last blood panel to your Health Passport so your ALT, AST and platelet trend sit in one place when you ask about FIB-4.
This article is for general education and is not a substitute for professional medical advice. Jaundice, abdominal swelling, confusion or vomiting blood require urgent medical assessment. Discuss any liver result with a qualified clinician.
Air pollution symptoms look almost identical to a viral infection. How to tell a pollution cough from a cold, which exposures actually matter, what protects you, and the warning signs that need a doctor rather than a mask.
Most coughs clear in under three weeks. If yours has not, the cause list changes completely. Whooping cough is surging in 2026, and there are six other explanations worth knowing before you ask for antibiotics that will not help.
PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, in May 2026 after an eleven year global consensus. The symptom cluster, how the diagnosis is made, the tests to ask for, and what the evidence says about metformin, inositol and GLP-1 medicines.